Dr. Butler’s long-term goal is to develop novel intracellular antibody (intrabody) therapeutics for neurodegenerative disorders caused by misfolded proteins. He has a broad background in degenerative diseases associated with aging. As a postdoc in the Messer lab, which pioneered the use of intracellular antibodies in the brain, David developed bifunctional intra-cellular antibodies. David’s bifunctional antibodies were able to prevent mutant Huntingtin and Synuclein from misfolding while directing them to the proteasome for degradation. He is currently utilizing induced pluripotent stem cell (iPSC) disease modeling to develop novel bifunctional intrabody reagents for tauopathies such as FTD and Alzheimer’s disease. Dr. Butler is also an Adjunct Professor in the Biomedical Sciences Department, School of Public Health, SUNY Albany.
EVENTS & ACTIVITIES (Speaking, Spoken, and Authored)